Prakt. lékáren. 2009; 5(5): 224-228

Psoriasis

MUDr. Helena Drozenová
Dermatovenerologická klinika 3. LF UK a FNKV, Praha

Psoriasis is among the most common skin conditions. It is a chronic inflammatory disease affecting about 2–3 % of the Central-European

population. In the Czech Republic, some 250,000 people suffer from psoriasis out of whom ten percent have very severe forms of the

disease.

Keywords: psoriasis, treatment, biologics.

Published: August 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drozenová H. Psoriasis. Praktické lékárenství. 2009;5(5):224-228.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Benáková N, Štork J. Léčba psoriázy biologiky. Čs. derm. 2006; 81(4)(Suppl.): 1-11.
    2. Benáková N, Štork J. Novinky v léčbě psoriázy biologiky a standardními systémovými léky. Čs. derm. 2008; 83(4): 191-202.
    3. Benáková N, Ettler K, Štork J, Vašků V. Psoriáza nejen pro praxi. Praha: Triton, 2007: 23-34, 56, 60, 131-136.
    4. Leonardi C, Menter A, Caro I, et al. Efalizumab: Results of a three-year continuous dosing study for the long term control of psoriasis. BJD 2008; 158: 1107-1116. Go to original source... Go to PubMed...
    5. Nast A. German evidence-based guidelines for treatment of Psoriasis vulgaris. Arch Dermatol Res 2007; 299: 111-138. Go to original source... Go to PubMed...
    6. Souhrn údajů o přípravku (SPC) uvedených biologik.
    7. Štork J, et al. Dermatovenerologie. Praha: Galén, 2008: 185-191.
    8. Vosmík F, a kol. Dermatovenerologie: Praha: Karolinum, 2001: 139 s.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.